Regression of Tumor Thrombus in the Suprahepatic Vena Cava of Hepatocellular Carcinoma and Conversion Hepatectomy Induced by Lenvatinib.

Dear Editor, Recent developments in systemic therapy for hepatocellular carcinoma (HCC) have been outstanding, and a response rate of 40.6% based on the modified RECIST criteria has been reported after lenvatinib (LEN) therapy for advanced HCC [[1]]. Preoperative LEN therapy might be a promising option among the multidisciplinary treatments for HCC with macroscopic HVTT. CT, computed tomography; TT, tumor thrombus; LEN, lenvatinib; IVC, inferior vena cava. [Extracted from the article]